Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb 24:6:22084.
doi: 10.1038/srep22084.

Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries

Collaborators, Affiliations

Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries

Tianhui Chen et al. Sci Rep. .

Abstract

We aimed at investigating the distribution and risk of second primary cancers (SPCs) in multiple myeloma (MM) survivors in Germany and Sweden to provide etiological understanding of SPCs and insight into their incidence rates and recording practices. MM patients diagnosed in 1997-2010 at age ≥15 years were selected from the Swedish (nationwide) and 12 German cancer registries. Standardized incidence ratios (SIRs) were used to assess risk of a specific SPC compared to risk of the same first cancer in the corresponding background population. Among 18,735 survivors of first MM in Germany and 7,560 in Sweden, overall 752 and 349 SPCs were recorded, respectively. Significantly elevated SIRs of specific SPCs were observed for acute myeloid leukemia (AML; SIR = 4.9) in Germany and for kidney cancer (2.3), AML (2.3) and nervous system cancer (1.9) in Sweden. Elevated risk for AML was more pronounced in the earlier diagnosis period compared to the later, i.e., 9.7 (4.2-19) for 1997-2003 period versus 3.5 (1.5-6.9) for 2004-2010 in Germany; 3.8 (1.4-8.3) for 1997-2003 versus 2.2 (0.3-7.8) for 2004-2010 in Sweden. We found elevated risk for AML for overall, early diagnosis periods and longer follow-up times in both populations, suggesting possible side effects of treatment for MM patients.

PubMed Disclaimer

References

    1. Landgren O. & Mailankody S. Update on second primary malignancies in multiple myeloma: a focused review. Leukemia, doi: 10.1038/leu.2014.22 (2014). - DOI - PubMed
    1. Sant M. et al.. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. The Lancet. Oncology 15, 931–942, doi: 10.1016/S1470-2045(14)70282-7 (2014). - DOI - PubMed
    1. Thomas A. et al.. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood 119, 2731–2737, doi: 10.1182/blood-2011-12-381426 (2012). - DOI - PMC - PubMed
    1. Palumbo A. et al.. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. The Lancet. Oncology 15, 333–342, doi: 10.1016/S1470-2045(13)70609-0 (2014). - DOI - PubMed
    1. Brenner H., Gondos A. & Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111, 2521–2526, doi: 10.1182/blood-2007-08-104984 (2008). - DOI - PubMed

Publication types

MeSH terms

Substances